China Inc by BBW
This week, Doug Young and Brad Burgess explore how Chinese companies are aggressively stepping out of their domestic market and onto the global stage. First, we dive into the booming trend of Chinese biopharma startups "out-licensing" their homegrown, cutting-edge drugs to Western pharmaceutical giants like Pfizer and Gilead. What's driving this rapid pace of innovation, and will geopolitics get in the way of future acquisitions? Then, we pivot from the lab to the track to look at Chinese sportswear brands like Xtep, Anta, and Li Ning. As these homegrown labels expand into Southeast Asia to challenge giants like Nike and Adidas, we discuss their strategic advantages, the geopolitical hurdles they face, and why a hyper-nationalistic image at home might be their biggest roadblock abroad. -- China Inc. by Bamboo Works [https://thebambooworks.com/] discusses the latest business and financial news from China and what it all means. This episode is hosted by Doug Young, Bamboo Works editor in chief, and he's joined by Brad Burgess, who is a reputation management advisor with over two decades of experience protecting and promoting brands and business leaders with a focus on Asia and specialty in China.
100 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de China Inc by BBW!